Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Syndevrx is raising $15,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Brad Carver played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Syndevrx

Our work has the potential to improve the lives of cancer patients worldwide. All of us know people who have suffered and perhaps even died due to cancer. SynDevRx is dedicated to developing treatments for the rising number of patients whose cancer is associated with metabolic dysfunction. SynDevRx the leader in the emerging  field of metabo-oncology is tackling this urgent and unmet medical need with its clinical drug SDX-7320.

To learn more about Syndevrx, visit http://www.syndevrx.com/

Contact:
Brad Carver, President and Chief Executive Officer
617-401-3110
bcarver@syndevrx.com
http://www.linkedin.com/in/brad-carver-a487523

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved